{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:22:00Z","timestamp":1791764520934,"version":"4.3.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Microbiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Poxviruses rely on a conserved multiprotein entry\u2013fusion complex, providing numerous potential antibody targets, although the immunogenicities of only a few have been analysed. Here we tested the ectodomains of ten orthopoxvirus entry\u2013fusion complex proteins in rabbit and mouse immunization experiments and determined that six induce neutralizing antibodies. Focusing on the apical A16\/G9 heterodimer, we show that it induces antibodies that prevent vaccinia virus (VACV) entry, cross-neutralize cowpox virus (CPXV) and monkeypox virus (MPXV), and protect mice against lethal challenge infections with VACV and CPXV. However, antibodies to A16\/G9 had limited detection following infections with attenuated or virulent VACV, CPXV or MPXV, but were robustly induced upon immunization with recombinant VACVs secreting G9 or that have deletions of the genes encoding the viral fusion suppressor A56\/K2 complex, which specifically binds A16\/G9. Our work identifies previously unrecognized immunogens for incorporation into recombinant vaccines and characterizes a mode of immune evasion via the A56\/K2 complex.<\/jats:p>","DOI":"10.1038\/s41564-026-02392-6","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T09:03:51Z","timestamp":1781082231000},"page":"2008-2020","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immunogenicity of poxvirus A16\/G9 entry\u2013fusion subcomplex and its restriction by A56\/K2 protein informs vaccine design"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2430-272X","authenticated-orcid":false,"given":"Huibin","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Resch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8916-3305","authenticated-orcid":false,"given":"Catherine A.","family":"Cotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tase","family":"Karamanolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Belghith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxinne A.","family":"Ignacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia L.","family":"Earl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary H.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2154-8564","authenticated-orcid":false,"given":"Bernard","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"2392_CR1","doi-asserted-by":"crossref","unstructured":"Zaeck, L. M. et al. Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals. Nat. Med. 29, 270\u2013278 (2022).","DOI":"10.1101\/2022.08.31.22279414"},{"key":"2392_CR2","doi-asserted-by":"crossref","unstructured":"Oom, A. L. et al. The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response. J. Virol. 99, e0025325 (2025).","DOI":"10.1128\/jvi.00872-25"},{"key":"2392_CR3","doi-asserted-by":"publisher","first-page":"553","DOI":"10.15585\/mmwr.mm7220a3","volume":"72","author":"AF Dalton","year":"2023","unstructured":"Dalton, A. F. et al. Estimated effectiveness of JYNNEOS vaccine in preventing mpox: a multijurisdictional case-control study\u2014United States, August 19, 2022\u2013March 31, 2023. MMWR Morb. Mortal. Wkly Rep. 72, 553\u2013558 (2023).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"2392_CR4","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41564-024-01690-1","volume":"9","author":"B Moss","year":"2024","unstructured":"Moss, B. Understanding the biology of monkeypox virus to prevent future outbreaks. Nat. Microbiol. 9, 1408\u20131416 (2024).","journal-title":"Nat. Microbiol."},{"key":"2392_CR5","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.it.2025.04.002","volume":"46","author":"H Yu","year":"2025","unstructured":"Yu, H., Resch, W. & Moss, B. Poxvirus structural biology for application to vaccine design. Trends Immunol. 46, 455\u2013470 (2025).","journal-title":"Trends Immunol."},{"key":"2392_CR6","doi-asserted-by":"publisher","first-page":"18572","DOI":"10.1073\/pnas.0509239102","volume":"102","author":"TG Senkevich","year":"2005","unstructured":"Senkevich, T. G., Ojeda, S., Townsley, A., Nelson, G. E. & Moss, B. Poxvirus multiprotein entry\u2013fusion complex. Proc. Natl Acad. Sci. USA 102, 18572\u201318577 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2392_CR7","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3390\/v4050688","volume":"4","author":"B Moss","year":"2012","unstructured":"Moss, B. Poxvirus cell entry: how many proteins does it take?. Viruses 4, 688\u2013707 (2012).","journal-title":"Viruses"},{"key":"2392_CR8","doi-asserted-by":"crossref","unstructured":"Mutz, P. et al. Exaptation of inactivated host enzymes for structural roles in orthopoxviruses and novel folds of virus proteins revealed by protein structure modeling. mBio 14, e0040823 (2023).","DOI":"10.1128\/mbio.00408-23"},{"key":"2392_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.semcdb.2016.07.015","volume":"60","author":"B Moss","year":"2016","unstructured":"Moss, B. Membrane fusion during poxvirus entry. Semin. Cell. Dev. Biol. 60, 89\u201396 (2016).","journal-title":"Semin. Cell. Dev. Biol."},{"key":"2392_CR10","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aec0254","volume":"12","author":"CS Lin","year":"2026","unstructured":"Lin, C. S. et al. Cryo-EM structure of the vaccinia virus entry fusion complex reveals a multicomponent fusion machinery. Sci. Adv. 12, eaec0254 (2026).","journal-title":"Sci. Adv."},{"key":"2392_CR11","doi-asserted-by":"publisher","first-page":"e1007826","DOI":"10.1371\/journal.ppat.1007826","volume":"15","author":"HW Chang","year":"2019","unstructured":"Chang, H. W. et al. Vaccinia viral A26 protein is a fusion suppressor of mature virus and triggers membrane fusion through conformational change at low pH. PLoS Pathog. 15, e1007826 (2019).","journal-title":"PLoS Pathog."},{"key":"2392_CR12","doi-asserted-by":"publisher","first-page":"5153","DOI":"10.1128\/JVI.00162-08","volume":"82","author":"TR Wagenaar","year":"2008","unstructured":"Wagenaar, T. R., Ojeda, S. & Moss, B. Vaccinia virus A56\/K2 fusion regulatory protein interacts with the A16 and G9 subunits of the entry fusion complex. J. Virol. 82, 5153\u20135160 (2008).","journal-title":"J. Virol."},{"key":"2392_CR13","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1128\/JVI.01706-07","volume":"82","author":"DH Davies","year":"2008","unstructured":"Davies, D. H. et al. Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus Ankara is comparable to that of Dryvax. J. Virol. 82, 652\u2013663 (2008).","journal-title":"J. Virol."},{"key":"2392_CR14","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.cell.2016.09.049","volume":"167","author":"I Gilchuk","year":"2016","unstructured":"Gilchuk, I. et al. Cross-neutralizing and protective human antibody specificities to poxvirus infections. Cell 167, 684\u2013694 e689 (2016).","journal-title":"Cell"},{"key":"2392_CR15","doi-asserted-by":"publisher","unstructured":"Yu, H. et al. Antibody binding and neutralizing targets within the predicted structure of the poxvirus multiprotein entry\u2013fusion complex. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2025.05.07.652617 (2025).","DOI":"10.1101\/2025.05.07.652617"},{"key":"2392_CR16","doi-asserted-by":"publisher","first-page":"13454","DOI":"10.1128\/JVI.79.21.13454-13462.2005","volume":"79","author":"S Lustig","year":"2005","unstructured":"Lustig, S. et al. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge. J. Virol. 79, 13454\u201313462 (2005).","journal-title":"J. Virol."},{"key":"2392_CR17","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.virol.2011.01.014","volume":"412","author":"CL Wolfe","year":"2011","unstructured":"Wolfe, C. L. & Moss, B. Interaction between the G3 and L5 proteins of the vaccinia virus entry\u2013fusion complex. Virology 412, 278\u2013283 (2011).","journal-title":"Virology"},{"key":"2392_CR18","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.virol.2007.05.015","volume":"366","author":"M Husain","year":"2007","unstructured":"Husain, M., Weisberg, A. S. & Moss, B. Resistance of a vaccinia virus A34R deletion mutant to spontaneous rupture of the outer membrane of progeny virions on the surface of infected cells. Virology 366, 424\u2013432 (2007).","journal-title":"Virology"},{"key":"2392_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-67230-z","volume":"10","author":"X Gao","year":"2020","unstructured":"Gao, X., Dong, X., Li, X., Liu, Z. & Liu, H. Prediction of disulfide bond engineering sites using a machine learning method. Sci. Rep. 10, 10330 (2020).","journal-title":"Sci. Rep."},{"key":"2392_CR20","doi-asserted-by":"publisher","first-page":"6244","DOI":"10.1128\/JVI.00434-08","volume":"82","author":"GE Nelson","year":"2008","unstructured":"Nelson, G. E., Wagenaar, T. R. & Moss, B. A conserved sequence within the H2 subunit of the vaccinia virus entry\/fusion complex is important for interaction with the A28 subunit and infectivity. J. Virol. 82, 6244\u20136250 (2008).","journal-title":"J. Virol."},{"key":"2392_CR21","doi-asserted-by":"publisher","first-page":"8899","DOI":"10.1128\/JVI.01053-06","volume":"80","author":"AC Townsley","year":"2006","unstructured":"Townsley, A. C., Weisberg, A. S., Wagenaar, T. R. & Moss, B. Vaccinia virus entry into cells via a low pH-dependent-endosomal pathway. J. Virol. 80, 8899\u20138908 (2006).","journal-title":"J. Virol."},{"key":"2392_CR22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.virol.2013.11.017","volume":"449","author":"JL Americo","year":"2014","unstructured":"Americo, J. L. et al. Susceptibility of the wild-derived inbred CAST\/Ei mouse to infection by orthopoxviruses analyzed by live bioluminescence imaging. Virology 449, 120\u2013132 (2014).","journal-title":"Virology"},{"key":"2392_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg3540","volume":"15","author":"AW Freyn","year":"2023","unstructured":"Freyn, A. W. et al. An mpox virus mRNA\u2013lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge. Sci. Transl. Med. 15, eadg3540 (2023).","journal-title":"Sci. Transl. Med."},{"key":"2392_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59826-8","volume":"16","author":"AA Belghith","year":"2025","unstructured":"Belghith, A. A. et al. Mpox multiprotein virus-like nanoparticle vaccine induces neutralizing and protective antibodies in mice and non-human primates. Nat. Commun. 16, 4726 (2025).","journal-title":"Nat. Commun."},{"key":"2392_CR25","doi-asserted-by":"crossref","unstructured":"Frey, S. et al. Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccination. Vaccine 69, 127959 (2026).","DOI":"10.1016\/j.vaccine.2025.127959"},{"key":"2392_CR26","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adl4317","volume":"16","author":"C Jacob-Dolan","year":"2024","unstructured":"Jacob-Dolan, C. et al. Comparison of the immunogenicity and protective efficacy of ACAM2000, MVA, and vectored subunit vaccines for Mpox in rhesus macaques. Sci. Transl. Med. 16, eadl4317 (2024).","journal-title":"Sci. Transl. Med."},{"key":"2392_CR27","doi-asserted-by":"publisher","first-page":"6266","DOI":"10.1016\/j.cell.2025.07.040","volume":"188","author":"A Meola","year":"2025","unstructured":"Meola, A. et al. Structural basis of poxvirus fusion regulation and anti-A16\/G9 antibody-mediated neutralization and protection. Cell 188, 6266\u20136282 e6218 (2025).","journal-title":"Cell"},{"key":"2392_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2217\/fmb.09.110","volume":"5","author":"M Moutaftsi","year":"2010","unstructured":"Moutaftsi, M. et al. Uncovering the interplay between CD8, CD4 and antibody responses to complex pathogens. Future Microbiol. 5, 221\u2013239 (2010).","journal-title":"Future Microbiol."},{"key":"2392_CR29","unstructured":"Moss, B. & Smith, G. L. in Fields Virology Vol. 2 (eds Howley, P. M. & Knipe, D. M.) 573\u2013613 (Wolters Kluwer, 2021)."},{"key":"2392_CR30","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1006\/viro.1996.0142","volume":"217","author":"Y Ichihashi","year":"1996","unstructured":"Ichihashi, Y. Extracellular enveloped vaccinia virus escapes neutralization. Virology 217, 478\u2013485 (1996).","journal-title":"Virology"},{"key":"2392_CR31","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1128\/JVI.80.1.51-61.2006","volume":"80","author":"S Ojeda","year":"2006","unstructured":"Ojeda, S., Senkevich, T. G. & Moss, B. Entry of vaccinia virus and cell\u2013cell fusion require a highly conserved cysteine-rich membrane protein encoded by the A16L gene. J. Virol. 80, 51\u201361 (2006).","journal-title":"J. Virol."},{"key":"2392_CR32","doi-asserted-by":"publisher","first-page":"9822","DOI":"10.1128\/JVI.00987-06","volume":"80","author":"S Ojeda","year":"2006","unstructured":"Ojeda, S., Domi, A. & Moss, B. Vaccinia virus G9 protein is an essential component of the poxvirus entry-fusion complex. J. Virol. 80, 9822\u20139830 (2006).","journal-title":"J. Virol."},{"key":"2392_CR33","doi-asserted-by":"crossref","unstructured":"Mirzakhanyan, Y. & Gershon, P. The vaccinia virion: filling the gap between atomic and ultrastructure. PLoS Pathog. 15, e1007508 (2019).","DOI":"10.1371\/journal.ppat.1007508"},{"key":"2392_CR34","doi-asserted-by":"crossref","unstructured":"Cotter, C. A. & Moss, B. Mutations near the N-terminus of the vaccinia virus G9 protein overcome restrictions on cell entry and syncytium formation imposed by the A56\/K2 fusion regulatory complex. J. Virol. 94, e00077-2 (2020).","DOI":"10.1128\/JVI.00077-20"},{"key":"2392_CR35","doi-asserted-by":"crossref","unstructured":"Hong, G. C., Tsai, C. H. & Chang, W. Experimental evolution to isolate vaccinia virus adaptive G9 mutants that overcome membrane fusion inhibition via the vaccinia virus A56\/K2 protein complex. J. Virol. 94, e00093-20 (2020).","DOI":"10.1128\/JVI.00093-20"},{"key":"2392_CR36","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1128\/JVI.01684-08","volume":"83","author":"TR Wagenaar","year":"2009","unstructured":"Wagenaar, T. R. & Moss, B. Expression of the A56 and K2 proteins is sufficient to inhibit vaccinia virus entry and cell fusion. J. Virol. 83, 1546\u20131554 (2009).","journal-title":"J. Virol."},{"key":"2392_CR37","doi-asserted-by":"publisher","first-page":"5989","DOI":"10.1073\/pnas.0601025103","volume":"103","author":"M Law","year":"2006","unstructured":"Law, M., Carter, G. C., Roberts, K. L., Hollinshead, M. & Smith, G. L. Ligand-induced and non-fusogenic dissolution of a viral membrane. Proc. Natl Acad. Sci. USA 103, 5989\u20135994 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2392_CR38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.virol.2004.07.024","volume":"328","author":"S Lustig","year":"2004","unstructured":"Lustig, S., Fogg, C., Whitbeck, J. C. & Moss, B. Synergistic neutralizing activities of antibodies to outer membrane proteins of the two infectious forms of vaccinia virus in the presence of complement. Virology 328, 30\u201335 (2004).","journal-title":"Virology"},{"key":"2392_CR39","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2220669120","volume":"120","author":"M Garcia-Sanchez","year":"2023","unstructured":"Garcia-Sanchez, M., Castro, M. & Faro, J. B cell receptors and free antibodies have different antigen-binding kinetics. Proc. Natl Acad. Sci. USA 120, e2220669120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2392_CR40","unstructured":"Meechan, P. J. & Potts, J. Biosafety in Microbiological and Biomedical Laboratories (BMBL) 6th edn (US Government Printing Office, 2020)."},{"key":"2392_CR41","doi-asserted-by":"publisher","first-page":"8613","DOI":"10.1128\/JVI.00606-07","volume":"81","author":"AC Townsley","year":"2007","unstructured":"Townsley, A. C. & Moss, B. Two distinct low-pH steps promote entry of vaccinia virus. J. Virol. 81, 8613\u20138620 (2007).","journal-title":"J. Virol."},{"key":"2392_CR42","doi-asserted-by":"publisher","first-page":"e1002446","DOI":"10.1371\/journal.ppat.1002446","volume":"7","author":"JP Laliberte","year":"2011","unstructured":"Laliberte, J. P., Weisberg, A. S. & Moss, B. The membrane fusion step of vaccinia virus entry is cooperatively mediated by multiple viral proteins and host cell components. PLoS Pathog. 7, e1002446 (2011).","journal-title":"PLoS Pathog."},{"key":"2392_CR43","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.virol.2013.12.030","volume":"452","author":"RJ Kastenmayer","year":"2014","unstructured":"Kastenmayer, R. J. et al. Elimination of A-type inclusion formation enhances cowpox virus replication in mice: Implications for orthopoxvirus evolution. Virology 452, 59\u201366 (2014).","journal-title":"Virology"},{"key":"2392_CR44","doi-asserted-by":"publisher","first-page":"161611","DOI":"10.1002\/cpmb.33","volume":"117","author":"CA Cotter","year":"2017","unstructured":"Cotter, C. A., Earl, P. L., Wyatt, L. S. & Moss, B. Preparation of cell cultures and vaccinia virus stocks. Curr. Protoc. Mol. Biol. 117, 161611\u2013161618 (2017).","journal-title":"Curr. Protoc. Mol. Biol."},{"key":"2392_CR45","doi-asserted-by":"publisher","first-page":"4590","DOI":"10.1073\/pnas.0401165101","volume":"101","author":"LS Wyatt","year":"2004","unstructured":"Wyatt, L. S., Earl, P. L., Eller, L. A. & Moss, B. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc. Natl Acad. Sci. USA 101, 4590\u20134595 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2392_CR46","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1128\/jvi.68.2.766-775.1994","volume":"68","author":"WP Sisk","year":"1994","unstructured":"Sisk, W. P. et al. High level expression and purification of secreted forms of herpes simplex virus type 1 glycoprotein gD synthesized by baculovirus-infected insect cells. J. Virol. 68, 766\u2013775 (1994).","journal-title":"J. Virol."},{"key":"2392_CR47","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.pep.2017.01.003","volume":"132","author":"C Attallah","year":"2017","unstructured":"Attallah, C., Etcheverrigaray, M., Kratje, R. & Oggero, M. A highly efficient modified human serum albumin signal peptide to secrete proteins in cells derived from different mammalian species. Protein Expr. Purif. 132, 27\u201333 (2017).","journal-title":"Protein Expr. Purif."},{"key":"2392_CR48","doi-asserted-by":"publisher","first-page":"10684","DOI":"10.1128\/JVI.77.19.10684-10688.2003","volume":"77","author":"PL Earl","year":"2003","unstructured":"Earl, P. L., Americo, J. L. & Moss, B. Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein. J. Virol. 77, 10684\u201310688 (2003).","journal-title":"J. Virol."},{"key":"2392_CR49","doi-asserted-by":"publisher","first-page":"161711","DOI":"10.1002\/cpmb.32","volume":"117","author":"LS Wyatt","year":"2017","unstructured":"Wyatt, L. S., Earl, P. L. & Moss, B. Generation of recombinant vaccinia viruses. Curr. Protoc. Mol. Biol. 117, 161711\u2013161718 (2017).","journal-title":"Curr. Protoc. Mol. Biol."}],"container-title":["Nature Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41564-026-02392-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-026-02392-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-026-02392-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:36:19Z","timestamp":1782920179000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41564-026-02392-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":49,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["2392"],"URL":"https:\/\/doi.org\/10.1038\/s41564-026-02392-6","relation":{},"ISSN":["2058-5276"],"issn-type":[{"value":"2058-5276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"6 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.Y., B.M. and W.R. are inventors on US government patent applications US20260069682A1. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}